Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024.